four-point preprandial self-monitoring of blood glucose for the assessment of glycemic control and variability in patients with type 2 diabetes treated with insulin and vildagliptin

Clicks: 298
ID: 248580
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #26 of 149 articles by views in zhonghua wei zhong bing ji jiu yi xue

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 149 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. This analysis utilized data from a double-blind, randomized, placebo-controlled crossover study in 29 patients with type 2 diabetes treated with vildagliptin or placebo on top of stable insulin dose. During two 4-week treatment periods, self-monitoring of plasma glucose was undertaken at 4 occasions every day. Glucose values were used to assess several indices of glycemic control quality, such as glucose mean, GRADE, M-VALUE, hypoglycemia and hyperglycemia index, and indices of glycemic variability, such as standard deviation, CONGA, J-INDEX, and MAGE. We found that vildagliptin improved the glycemic condition compared to placebo: mean glycemic levels, and both GRADE and M-VALUE, were reduced by vildagliptin (P<0.01). Indices also showed that vildagliptin reduced glycemia without increasing the risk for hypoglycemia. Almost all indices of glycemic variability showed an improvement of the glycemic condition with vildagliptin (P<0.02), though more marked differences were shown by the more complex indices. In conclusion, the study shows that four-sample preprandial glucose self-monitoring is sufficient to yield information on the vildagliptin effects on glycemic control and variability.
Reference Key
tura2015internationalfour-point Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Andrea Tura, Johan Farngren, Anja Schweizer, James E. Foley, Giovanni Pacini, Bo Ahrén
Are you one of these authors? Claim your profile
Journal zhonghua wei zhong bing ji jiu yi xue
Year 2015
DOI
10.1155/2015/484231
URL
http://dx.doi.org/10.1155/2015/484231
Keywords
clinical endocrinology diseases of the endocrine glands

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.